{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:05:09Z","timestamp":1793689509192,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.mehy.2017.12.029","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T13:11:15Z","timestamp":1514898675000},"page":"90-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature"],"prefix":"10.1016","volume":"111","author":[{"given":"Susan L.","family":"McElroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna I.","family":"Guerdjikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Paul E.","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2017.12.029_b0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"9","key":"10.1016\/j.mehy.2017.12.029_b0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.biopsych.2012.11.020","article-title":"The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys","volume":"73","author":"Kessler","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40519-016-0264-x","article-title":"A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder","volume":"21","author":"Agh","year":"2016","journal-title":"Eat Weight Disord"},{"issue":"4","key":"10.1016\/j.mehy.2017.12.029_b0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/eat.22501","article-title":"Mortality in eating disorders \u2013 results of a large prospective clinical longitudinal study","volume":"49","author":"Fichter","year":"2016","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.mehy.2017.12.029_b0025","doi-asserted-by":"crossref","unstructured":"McElroy SL, Guerdjikova AI, Mori N, Keck PE, Jr. Pharmacotherapy of the eating disorders. In: Stewart Agras W, Robinson A, eds. The Oxford Handbook of Eating Disorders, Second Edition. New York, NY 2017.","DOI":"10.1093\/oxfordhb\/9780190620998.013.20"},{"issue":"6","key":"10.1016\/j.mehy.2017.12.029_b0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1530\/EJE-09-0101","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"160","author":"Monami","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"9701","key":"10.1016\/j.mehy.2017.12.029_b0035","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1753-0407.12198","article-title":"Weight loss effect of glucagon-like peptide-1 mimetics on obese\/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2015","journal-title":"J Diabetes"},{"issue":"1","key":"10.1016\/j.mehy.2017.12.029_b0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/obr.12465","article-title":"Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity","volume":"18","author":"Burcelin","year":"2017","journal-title":"Obes Rev"},{"key":"10.1016\/j.mehy.2017.12.029_b0050","series-title":"Handbook of Behavior, Food and Nutrition","article-title":"The role of glucagon-like peptide-1 (Glp-1) in eating behavior","author":"Covasa","year":"2011"},{"issue":"10","key":"10.1016\/j.mehy.2017.12.029_b0055","doi-asserted-by":"crossref","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6560","key":"10.1016\/j.mehy.2017.12.029_b0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mehy.2017.12.029_b0065","first-page":"4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7\u201336) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2017.12.029_b0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuint.2013.10.003","article-title":"Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward","volume":"73","author":"Reddy","year":"2014","journal-title":"Neurochem Int"},{"key":"10.1016\/j.mehy.2017.12.029_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2017.91","article-title":"A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling","author":"Hsu","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.mehy.2017.12.029_b0085","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.biopsych.2008.09.028","article-title":"Binge-eating disorder: reward sensitivity and brain activation to images of food","volume":"65","author":"Schienle","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.mehy.2017.12.029_b0090","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.mehy.2017.12.029_b0095","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials","author":"O'Neil","year":"2017","journal-title":"Diabetes, Obesity Metabolism"},{"issue":"7","key":"10.1016\/j.mehy.2017.12.029_b0100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.mehy.2017.12.029_b0105","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/14656566.2016.1198776","article-title":"Managing comorbid obesity and depression through clinical pharmacotherapies","volume":"17","author":"McElroy","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.mehy.2017.12.029_b0110","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1172\/JCI74726","article-title":"Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice","volume":"124","author":"Cao","year":"2014","journal-title":"J Clin Invest"},{"issue":"171","key":"10.1016\/j.mehy.2017.12.029_b0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.physbeh.2016.12.034","article-title":"Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice","volume":"15","author":"Yamaguchi","year":"2017","journal-title":"Physiol Behav"},{"issue":"10","key":"10.1016\/j.mehy.2017.12.029_b0120","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1523\/JNEUROSCI.2212-10.2011","article-title":"Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function","volume":"31","author":"Barrera","year":"2011","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.mehy.2017.12.029_b0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.psychres.2008.06.040","article-title":"Glucagon-like peptide-1 secretion in bulimia nervosa","volume":"169","author":"Brambilla","year":"2009","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.1016\/j.mehy.2017.12.029_b0130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3945\/ajcn.111.014837","article-title":"Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal","volume":"94","author":"Naessen","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.mehy.2017.12.029_b0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/eat.22264","article-title":"Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa","volume":"48","author":"Dossat","year":"2015","journal-title":"Int J Eat Disord"},{"issue":"5","key":"10.1016\/j.mehy.2017.12.029_b0140","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.physbeh.2008.04.013","article-title":"Appetite-related gut peptides, ghrelin, PYY, and GLP-1 in obese women with and without binge eating disorder (BED)","volume":"94","author":"Geliebter","year":"2008","journal-title":"Physiol Behav"},{"issue":"1","key":"10.1016\/j.mehy.2017.12.029_b0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0306-4603(82)90024-7","article-title":"The assessment of binge eating severity among obese persons","volume":"7","author":"Gormally","year":"1982","journal-title":"Addict Behav"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide \u2013 a pilot study","volume":"9","author":"Robert","year":"2015","journal-title":"Obes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.mehy.2017.12.029_b0155","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/jn\/134.9.2372","article-title":"The Three-Factor Eating Questionnaire-R18 is able to distinguish among different eating patterns in a general population","volume":"134","author":"de Lauzon","year":"2004","journal-title":"J Nutr"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocr Res"},{"issue":"109","key":"10.1016\/j.mehy.2017.12.029_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.appet.2016.11.010","article-title":"Binge eating behaviours and food cravings in women with Polycystic Ovary Syndrome","volume":"01","author":"Jeanes","year":"2017","journal-title":"Appetite"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.mehy.2017.12.029_b0175","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.biopsych.2006.08.008","article-title":"Topiramate for the treatment of binge eating disorder associated with obesity: A placebo-controlled study","volume":"61","author":"McElroy","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.mehy.2017.12.029_b0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/EJE-12-0997","article-title":"GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases","volume":"168","author":"Zoicas","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"10.1016\/j.mehy.2017.12.029_b0185","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2169\/internalmedicine.53.1646","article-title":"Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity","volume":"53","author":"Ando","year":"2014","journal-title":"Intern Med"},{"issue":"10","key":"10.1016\/j.mehy.2017.12.029_b0190","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1507\/endocrj.EJ12-0074","article-title":"The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome","volume":"59","author":"Senda","year":"2012","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.mehy.2017.12.029_b0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ijpo.12131","article-title":"Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome","volume":"12","author":"Salehi","year":"2017","journal-title":"Pediatr Obes"},{"issue":"5","key":"10.1016\/j.mehy.2017.12.029_b0200","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/npp.2015.275","article-title":"Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: Results of two pivotal phase 3 randomized controlled trials","volume":"41","author":"McElroy","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.mehy.2017.12.029_b0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpsyc.1992.01820020059008","article-title":"Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial","volume":"49","author":"Fluoxetine Bulimia Nervosa Collaborative Study Group","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.mehy.2017.12.029_b0210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1192\/bjp.166.5.660","article-title":"Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group","volume":"166","author":"Goldstein","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.mehy.2017.12.029_b0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2017.1889","article-title":"Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial","author":"Hudson","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2017.12.029_b0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1176\/appi.ajp.159.1.96","article-title":"A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment","volume":"159","author":"Romano","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mehy.2017.12.029_b0225","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-017-4354-8","article-title":"GLP-1\/glucagon receptor co-agonism for treatment of obesity","author":"Sanchez-Garrido","year":"2017","journal-title":"Diabetologia"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717309076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717309076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T19:12:08Z","timestamp":1570561928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987717309076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":45,"alternative-id":["S0306987717309076"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2017.12.029","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2017.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}